Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ORLWR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
40287441 3D1 MMAE
|
|||||
| Synonyms |
3D1 MMAE
Click to Show/Hide
|
|||||
| Organization |
Dana-Farber Cancer Institute.; National Hospital Organization Tokyo Medical Center.; Keio University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
MUC1 3D1
|
Antibody Info | ||||
| Antigen Name |
Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation using new Q-tag substrate of bacterial transglutaminase
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.8 nM | Positive MUC1-C expression (MUC1-C+++/++) | ||
| Method Description |
Cells were seeded at a density of 1500-3500 cells per well in 96-well plates. The next day, the cells were treated with different concentrations of the drug. Cell viability and proliferation were assessed using the Alamar Blue Reagent (cat# DAL1100, Thermo Fisher Scientific) following the company protocol. The IC50 values were determined by nonlinear regression of the dose-response data using Prism 10.0 (SCR_002798, GraphPad Software). Fluorescence intensity (560 nm excitation/590 nm emission) was measured in at least triplicate wells.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | MCF-7 cells (ER (D538G)) | CVCL_0031 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 6.3 nM | Positive MUC1-C expression (MUC1-C+++/++) | ||
| Method Description |
Cells were seeded at a density of 1500-3500 cells per well in 96-well plates. The next day, the cells were treated with different concentrations of the drug. Cell viability and proliferation were assessed using the Alamar Blue Reagent (cat# DAL1100, Thermo Fisher Scientific) following the company protocol. The IC50 values were determined by nonlinear regression of the dose-response data using Prism 10.0 (SCR_002798, GraphPad Software). Fluorescence intensity (560 nm excitation/590 nm emission) was measured in at least triplicate wells.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 27 nM | Positive MUC1-C expression (MUC1-C+++/++) | ||
| Method Description |
Cells were seeded at a density of 1500-3500 cells per well in 96-well plates. The next day, the cells were treated with different concentrations of the drug. Cell viability and proliferation were assessed using the Alamar Blue Reagent (cat# DAL1100, Thermo Fisher Scientific) following the company protocol. The IC50 values were determined by nonlinear regression of the dose-response data using Prism 10.0 (SCR_002798, GraphPad Software). Fluorescence intensity (560 nm excitation/590 nm emission) was measured in at least triplicate wells.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | MCF-7 cells (ER (Y537S)) | CVCL_0031 | ||
References